etoposide has been researched along with Learning Disabilities in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bohgaki, M; Bohgaki, T; Bristow, R; Cheung, P; El Ghamrasni, S; Eldin, MS; Guturi, KKN; Hakem, A; Hakem, R; Jeon, J; Kumareswaran, R; Ng, D; Patel, P; Raught, B; Srikumar, T; Stewart, GS | 1 |
Jereb, B; Macedoni-Luksic, M; Todorovski, L | 1 |
2 other study(ies) available for etoposide and Learning Disabilities
Article | Year |
---|---|
RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromosome Segregation; Craniofacial Abnormalities; DNA Topoisomerases, Type II; DNA, Catenated; Drug Resistance, Neoplasm; Etoposide; Fibroblasts; Gene Knockdown Techniques; HEK293 Cells; Humans; Immunologic Deficiency Syndromes; Learning Disabilities; Mice; Mutagenesis, Site-Directed; Neoplasms; Poly-ADP-Ribose Binding Proteins; Primary Immunodeficiency Diseases; Proteomics; RNA, Small Interfering; Topoisomerase II Inhibitors; Ubiquitin Thiolesterase; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Brain Damage, Chronic; Brain Neoplasms; Calcinosis; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disabled Children; Epilepsy; Etoposide; Female; Humans; Hydrocephalus; Infant; Intellectual Disability; Learning Disabilities; Lomustine; Magnetic Resonance Imaging; Male; Methotrexate; Movement Disorders; Neoplasm Recurrence, Local; Prevalence; Procarbazine; Radiation Injuries; Slovenia; Survivors; Tomography, X-Ray Computed; Unemployment; Vincristine; Vision Disorders | 2003 |